Loading…

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

meRfi® AI Chat

NCT02469558 - Bifidobacterium animalis lactis W51 + Bifidobacterium animalis lactis W52 + Bifidobacterium bifidum W23 + Fructooligosaccharides (FOS P6) + Galactooligosaccharides (GOS P11) + Lacticaseibacillus casei W56 + Lactobacillus acidophilus W37 + Levilactobacillus brevis W63 + Ligilactobacillus salivarius W24 + Lactococcus lactis W19 + Lactococcus lactis W58 & Diabesity

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background

Diabesity, which refers to the combination of obesity and type 2 diabetes, is increasingly becoming a significant global health issue. The dysbiosis of the gut microbiota associated with diabesity has attracted attention as it may play a role in the development of the disease. Consequently, this has opened up the possibility of targeting it therapeutically through the use of pro- or prebiotic supplements (1)

Study overview

This is a randomized clinical prevention trial studying a daily dose of [Bifidobacterium bifidum W23 + Bifidobacterium lactis W52 + Bifidobacterium lactis W51 +…

References (Sources)

Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study
Horvath et al. 2020 Eur J Nutr 59(7): 2969-2983

AI Chat

7/2/2026

Chat with our artificial intelligence:

Start chat!